Core A will fulfill three major functions. One function is the overall management of the POI, which will be the responsibility of the Pl (Steven Balk) and the co-investigator (Peter Nelson). They will insure that administrative and regulatory requirements are met, but their main focuses will be on enhancing communication and collaboration between the Projects and on optimizing the use of the resources provided by the P01. The second function of the Core is to assist the Projects in efforts to translate their findings into patients. In addition to Drs. Balk and Nelson, Core A includes three investigators with a major focus on the design and conduct of clinical trials in prostate cancer (Drs. Mary-Ellen Taplin, Bruce Montgomery, and Glenn Bubley). Through previous/ongoing clinical trials and tissue banking efforts at their respective institutions, these investigators have collected valuable tissue and serum samples from patients at varying stages of their disease and after varying therapies. In discussions with the Project Leaders, they will facilitate the identification and distribution of relevant coded clinical samples for analysis by the Projects, and will assist in interpreting the clinical significance of the results. Moreover, Drs. Taplin, Montgomery and Bubley will assist the Project Leaders in the design and conduct of preclinical studies that can form the foundation for subsequent phase I or phase 11 clinical trials. The third Core function is to provide statistical support for each of the Project Leaders in their experimental designs. Lillian Werner, in the Department of Biostatistics and Computational Biology at DFCI, who also directs the DF/HCC Prostate Cancer SPORE Biostatistics and Computational Biology Core, is dedicating 10% effort specifically to this P01.
The specific aims are:
Aim 1. Provide administrative support to insure that the goals of the project are achieved.
Aim 2. Assist in translating the results from each Project into the clinic.
Aim 3. Provide biostatistical support for each Project.

Public Health Relevance

The objectives of Core A are to 1) provide administrative support to insure that the goals of the project are achieved;2) assist in translating the results from each Project into the clinic;and 3) provide biostatistical support for each Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA163227-02
Application #
8765217
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
2
Fiscal Year
2014
Total Cost
$133,318
Indirect Cost
$7,381
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Beshiri, Michael L; Tice, Caitlin M; Tran, Crystal et al. (2018) A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res 24:4332-4345
Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Arai, Seiji; Jonas, Oliver; Whitman, Matthew A et al. (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24:5458-5470
Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362
Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735
Penning, Trevor M (2018) Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer. Vitam Horm 108:309-331

Showing the most recent 10 out of 90 publications